The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing
Open accessAbstract
Trastuzumab-based therapy has been shown to confer overall survival benefit in HER2-positive patients with advanced gastric cancer in a large multicentric trial (ToGA study). Subgroup analysis identified adenocarcinomas of the stomach and gastroesophageal (GE) junction with overexpression of HER2 according to immunohistochemistry (IHC) as potential responders. Due to recent approval of trastuzumab for HER2 positive metastatic gastric and GE-junction cancer in Europe (EMEA) HER2 diagnostics is now mandatory with IHC being the primary test followed by fluorescence in situ hybridization (FISH) in IHC2+ cases. However, in order to not miss patients potentially responding to targeted therapy determination of a HER2-positive status for gastric cancer required modification of scoring as had been proposed in a pre-ToGA study. To validate this new HER2 status testing procedure in terms of inter-laboratory and inter-observer consensus for IHC scoring a series of 547 gastric cancer tissue samples on a tissue microarray (TMA) was used. In the first step, 30 representative cores were used to identify specific IHC HER2 scoring issues among eight French and German laboratories, while in the second step the full set of 547 cores was used to determine IHC HER2 intensity and area score concordance between six German pathologists. Specific issues relating to discordance were identified and recommendations formulated which proved to be effective to reliably determine HER2 status in a prospective test series of 447 diagnostic gastric cancer specimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 1×
“Monitoring of the tumor HER2 status (gene amplification and/or protein overexpression) in breast cancer has become routine as the positive HER2 status detected in around 25% of these cancers is associated with poorer prognosis, more aggressive disease, and an increased risk of disease recurrence [3–5].”
BackgroundSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“Furthermore, in breast cancer the determination of HER2 status is necessary for optimal application of HER2-directed therapies such as trastuzumab (Herceptin®, Roche), which increases overall survival in both the metastatic [6, 7] and adjuvant settings [8–10], and predicts response in the neo-adjuvant setting [9, 10].”
BackgroundBang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Self-citationStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Smith, I., Procter, M., Gelber, R. D., Guillaume, S., Feyereislova, A., Dowsett, M., Goldhirsch, A., Untch, M., Mariani, G., Baselga, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60028-2 · Cited by 1,507
Lamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
Assessment of a HER2 scoring system for gastric cancer: results from a validation study
Hofmann, M., Stoss, O., Shi, D., Büttner, R., Van De Vijver, M., Kim, W., Ochiai, A., Rüschoff, J., & Henkel, T. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03028.x · Cited by 1,187
Self-citationRoss, J. S., & Fletcher, J. A. (1998) · STEM CELLS · doi:10.1002/stem.160413 · Cited by 985
Tanner, M., Hollmén, M., Junttila, T. T., Kapanen, A. I., Tommola, S., Soini, Y., Helin, H., Salo, J., Joensuu, H., Sihvo, E., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi064 · Cited by 665
Integration and generalization of kappas for multiple raters
Conger, A. J. (1980) · Psychological Bulletin · doi:10.1037/0033-2909.88.2.322 · Cited by 545
Nakajima, M., Sawada, H., Yamada, Y., Watanabe, A., Tatsumi, M., Yamashita, J., Matsuda, M., Sakaguchi, T., Hirao, T., & Nakano, H. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990501)85:9%3c1894::aid-cncr3%3e3.0.co;2-j · Cited by 494
HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer
Park, D. I., Yun, J. W., Park, J. H., Oh, S. J., Kim, H. J., Cho, Y. K., Sohn, C. I., Jeon, W. K., Kim, B. I., Yoo, C. H., et al. (2006) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-9057-1 · Cited by 329
Patterns of HER-2/neu Amplification and Overexpression in Primary and Metastatic Breast Cancer
Simon, R., Nocito, A., Hubscher, T., Bucher, C., Torhorst, J., Schraml, P., Bubendorf, L., Mihatsch, M. M., Moch, H., Wilber, K., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.15.1141 · Cited by 290
Allgayer, H., Babic, R., Gruetzner, K. U., Tarabichi, A., Schildberg, F. W., & Heiss, M. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2201 · Cited by 276
Ross, J. S., & Fletcher, J. A. (1998) · The Oncologist · doi:10.1634/theoncologist.3-4-237 · Cited by 260
Van Cutsem, E., Kang, Y., Chung, H., Sawaki, A., Lordick, F., Hill, J., Lehle, M., Feyereislova, A., & Bang, Y. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.lba4509 · Cited by 203
Fujimoto-Ouchi, K., Sekiguchi, F., Yasuno, H., Moriya, Y., Mori, K., & Tanaka, Y. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0337-z · Cited by 193
Dowsett, M., Procter, M., McCaskill-Stevens, W., de Azambuja, E., Dafni, U., Rueschoff, J., Jordan, B., Dolci, S., Abramovitz, M., Stoss, O., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.7939 · Cited by 180
Barros-Silva, J. D., Leitão, D., Afonso, L., Vieira, J., Dinis-Ribeiro, M., Fragoso, M., Bento, M. J., Santos, L., Ferreira, P., Rêgo, S., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604885 · Cited by 178
Garc�a, I., Vizoso, F., Mart�n, A., Sanz, L., Abdel-Lah, O., Raigoso, P., & Garc�a-Mu�iz, J. L. (2003) · Annals of Surgical Oncology · doi:10.1245/aso.2003.05.010 · Cited by 177
HER2 Testing in Gastric Cancer
Albarello, L., Pecciarini, L., & Doglioni, C. (2011) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3182026d72 · Cited by 172
Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer
Zhang, X. L., Yang, Y. S., Xu, D. P., Qu, J. H., Guo, M. Z., Gong, Y., & Huang, J. (2009) · World Journal of Surgery · doi:10.1007/s00268-009-0142-z · Cited by 165
Arnould, L., Arveux, P., Couturier, J., Gelly-Marty, M., Loustalot, C., Ettore, F., Sagan, C., Antoine, M., Penault-Llorca, F. M., Vasseur, B., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3022 · Cited by 106
Self-citationCutsem, E. V., Kang, Y., Chung, H., Shen, L., Sawaki, A., Lordick, F., Hill, J., Lehle, M., Feyereislova, A., & Bang, Y. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.18_suppl.lba4509 · Cited by 90
Cited by
Van Cutsem, E., Sagaert, X., Topal, B., Haustermans, K., & Prenen, H. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30354-3 · Cited by 1,793
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Ajani, J. A., D’Amico, T. A., Bentrem, D. J., Chao, J., Cooke, D., Corvera, C., Das, P., Enzinger, P. C., Enzler, T., Fanta, P., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0008 · Cited by 1,684
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Iqbal, N., & Iqbal, N. (2014) · Molecular Biology International · doi:10.1155/2014/852748 · Cited by 1,381
Ajani, J. A., D’Amico, T. A., Bentrem, D. J., Chao, J., Corvera, C., Das, P., Denlinger, C. S., Enzinger, P. C., Fanta, P., Farjah, F., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0033 · Cited by 1,059
Metadata
- Authors
- Rüschoff, J., Dietel, M., Baretton, G., Arbogast, S., Walch, A., Monges, G., Chenard, M.-P., Penault-Llorca, F., Nagelmeier, I., Schlake, W., Höfler, H., & Kreipe, H. H.
- Venue
- Virchows Archiv
- Published
- 2010-07-28
- Volume
- 457
- Issue
- 3
- Pages
- 299-307
- ISSN
- 0945-6317 (ISSN-L)
- 1432-2307
- OpenAlex
- W2075657881
- Cited by
- 486
- References
- 27
- FWCI
- 21.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.